Profile data is unavailable for this security.
About the company
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
- Revenue in USD (TTM)525.66m
- Net income in USD-192.74m
- Incorporated2000
- Employees1.45k
- LocationNovocure LtdNo. 4 The Forum, Grenville StreetSAINT HELIER JE2 4UFJerseyJEY
- Phone+44 1 534756700
- Websitehttps://www.novocure.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inmode Ltd | 466.26m | 181.11m | 1.58bn | 581.00 | 8.89 | 1.90 | 8.72 | 3.40 | 2.11 | 2.11 | 5.42 | 9.87 | 0.5973 | 1.71 | 16.09 | 802,509.40 | 23.20 | 31.32 | 25.21 | 35.64 | 83.10 | 84.46 | 38.84 | 39.65 | 12.66 | -- | 0.00 | 0.00 | 8.32 | 37.49 | 22.54 | 54.65 | 13.10 | -- |
| Alphatec Holdings Inc | 511.63m | -191.60m | 1.64bn | 839.00 | -- | 44.52 | -- | 3.21 | -1.49 | -1.49 | 3.97 | 0.4294 | 0.7612 | 1.34 | 6.70 | 609,808.10 | -28.51 | -30.97 | -37.13 | -39.47 | 65.89 | 66.02 | -37.45 | -46.22 | 1.49 | -5.17 | 0.8938 | -- | 37.45 | 39.38 | -23.36 | -- | 67.92 | -- |
| Rxsight Inc | 101.10m | -44.50m | 1.84bn | 374.00 | -- | 10.70 | -- | 18.19 | -1.25 | -1.25 | 2.83 | 4.41 | 0.5243 | 2.01 | 5.91 | 270,323.50 | -23.07 | -- | -25.25 | -- | 63.39 | -- | -44.01 | -- | 8.18 | -- | 0.0009 | -- | 81.77 | -- | 27.19 | -- | -- | -- |
| LeMaitre Vascular Inc | 199.89m | 33.95m | 1.94bn | 614.00 | 57.30 | 6.29 | 44.63 | 9.71 | 1.51 | 1.51 | 8.89 | 13.74 | 0.5977 | 1.17 | 7.19 | 325,548.90 | 10.15 | 9.02 | 10.99 | 9.93 | 66.45 | 65.83 | 16.99 | 15.45 | 5.31 | -- | 0.00 | 40.41 | 19.69 | 12.88 | 45.89 | 5.96 | 18.93 | 15.51 |
| Warby Parker Inc | 697.80m | -55.06m | 1.96bn | 2.14k | -- | 6.21 | -- | 2.82 | -0.467 | -0.467 | 5.91 | 2.66 | 1.21 | 5.19 | 655.52 | 326,074.80 | -9.57 | -- | -11.95 | -- | 55.01 | 57.49 | -7.89 | -14.53 | 2.02 | -- | 0.00 | -- | 11.98 | 19.67 | 42.75 | -- | -- | -- |
| Novocure Ltd | 525.66m | -192.74m | 2.06bn | 1.45k | -- | 5.72 | -- | 3.91 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Premier Inc | 1.34bn | 80.33m | 2.07bn | 2.80k | 30.81 | 1.08 | 10.53 | 1.55 | 0.6421 | 0.6421 | 11.34 | 18.35 | 0.3887 | 5.25 | 3.10 | 477,306.10 | 1.89 | 10.39 | 2.48 | 13.00 | 66.20 | 62.04 | 4.87 | 22.60 | 0.8226 | 143.62 | 0.276 | 19.11 | -6.76 | 2.44 | -34.17 | -15.30 | -2.29 | -- |
| STAAR Surgical Co | 326.24m | 15.30m | 2.17bn | 1.06k | 142.99 | 5.53 | 104.99 | 6.66 | 0.3093 | 0.3093 | 6.62 | 8.00 | 0.7159 | 2.11 | 5.09 | 308,942.30 | 3.36 | 6.77 | 3.82 | 7.90 | 78.51 | 76.89 | 4.69 | 9.16 | 5.22 | -- | 0.0004 | 0.00 | 13.37 | 21.07 | -46.18 | 33.85 | 51.95 | -- |
| Conmed Corp | 1.26bn | 82.35m | 2.27bn | 4.00k | 28.07 | 2.65 | 14.69 | 1.80 | 2.62 | 2.62 | 40.12 | 27.76 | 0.545 | 1.73 | 5.55 | 315,387.00 | 3.56 | 0.8972 | 4.10 | 1.02 | 54.92 | 54.95 | 6.53 | 1.65 | 1.08 | 3.65 | 0.5369 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
| Patterson Companies, Inc. | 6.57bn | 185.93m | 2.32bn | 7.60k | 13.19 | 2.36 | 8.46 | 0.3525 | 2.00 | 2.00 | 70.16 | 11.16 | 2.27 | 6.58 | 12.82 | 864,246.30 | 6.42 | 1.13 | 11.05 | 1.81 | 21.01 | 20.98 | 2.82 | 0.5157 | 0.7473 | 14.91 | 0.389 | 304.75 | 1.50 | 3.34 | -10.42 | 18.10 | 2.17 | 0.00 |
| Quidelortho Corp | 2.86bn | -1.76bn | 2.33bn | 7.10k | -- | 0.7038 | -- | 0.8153 | -26.38 | -26.38 | 42.82 | 49.52 | 0.3696 | 2.67 | 8.92 | 403,197.20 | -22.79 | 11.34 | -25.57 | 12.91 | 48.13 | 62.71 | -61.65 | 20.93 | 0.807 | 0.8786 | 0.4207 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
| 10X Genomics Inc | 625.45m | -264.30m | 2.38bn | 1.26k | -- | 3.30 | -- | 3.80 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Evolent Health Inc | 2.18bn | -141.23m | 2.42bn | 4.70k | -- | 2.28 | -- | 1.11 | -1.25 | -1.25 | 19.28 | 10.72 | 0.8316 | -- | 6.30 | 462,948.70 | -4.22 | -9.60 | -5.36 | -12.59 | 20.56 | 24.50 | -5.07 | -13.66 | -- | -0.0548 | 0.3272 | -- | 45.26 | 25.65 | -660.71 | -- | -6.18 | -- |
| UFP Technologies Inc | 407.33m | 47.88m | 2.43bn | 3.09k | 51.04 | 8.24 | 40.84 | 5.97 | 6.21 | 6.21 | 52.82 | 38.46 | 1.02 | 4.50 | 6.71 | 131,693.20 | 11.99 | 9.69 | 13.80 | 10.95 | 27.89 | 26.33 | 11.75 | 10.14 | 1.46 | 17.87 | 0.1039 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
| Myriad Genetics, Inc. | 774.20m | -234.60m | 2.45bn | 2.70k | -- | 3.23 | -- | 3.17 | -2.82 | -2.82 | 9.11 | 8.40 | 0.6792 | 10.41 | 6.53 | 286,740.80 | -20.58 | -- | -23.57 | -- | 68.79 | -- | -30.30 | -- | 1.82 | -225.20 | 0.0485 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Integra Lifesciences Holdings Corp | 1.53bn | 40.23m | 2.49bn | 3.95k | 62.32 | 1.56 | 15.28 | 1.63 | 0.5079 | 0.5079 | 19.32 | 20.29 | 0.3912 | 1.56 | 6.06 | 387,632.80 | 1.03 | 3.33 | 1.11 | 3.68 | 61.48 | 63.67 | 2.63 | 7.99 | 3.35 | 6.66 | 0.5374 | 0.00 | -1.03 | 0.9219 | -62.48 | 2.19 | -2.97 | -- |
Data as of Jul 22 2024. Currency figures normalised to Novocure Ltd's reporting currency: US Dollar USD
51.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 16.06m | 14.93% |
| The Vanguard Group, Inc.as of 28 Jun 2024 | 11.13m | 10.34% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 8.86m | 8.24% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.91m | 5.49% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.36m | 3.13% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 2.31m | 2.15% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.25m | 2.09% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 1.99m | 1.85% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.64m | 1.53% |
| Nordwand Advisors LLCas of 31 Mar 2024 | 1.52m | 1.41% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
